Details
Stereochemistry | ACHIRAL |
Molecular Formula | C6H6O2 |
Molecular Weight | 110.1106 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=CC(O)=CC=C1
InChI
InChIKey=GHMLBKRAJCXXBS-UHFFFAOYSA-N
InChI=1S/C6H6O2/c7-5-2-1-3-6(8)4-5/h1-4,7-8H
DescriptionCurator's Comment: Description was created based on several sources, including https://www.drugs.com/mtm/resorcinol-topical.html and
http://www.fda.gov/downloads/Drugs/.../Guidances/UCM259744.pdf
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/mtm/resorcinol-topical.html and
http://www.fda.gov/downloads/Drugs/.../Guidances/UCM259744.pdf
Resorcinol is a benzenediol. Resorcinol is commonly used in hair dyes and acne medication. Resorcinol works by breaking down rough, scaly, or hardened skin. Resorcinol also disinfects the skin to help fight infection. Resorcinol topical (for the skin) is used to treat pain and itching caused by minor cuts and scrapes, burns, insect bites, poison ivy, sunburn, or other skin irritations. Resorcinol topical is also used to treat acne, eczema, psoriasis, seborrhea, corns, calluses, warts, and other skin disorders. Resorcinol is included in the FDA final rule list of all permitted active ingredients for OTC topical acne products. Permitted combination active ingredient product - Resorcinol in 2 percent concentration in combination with sulfur in concentrations of between 3 and 8 percent. In oxidative hair dyes, resorcinol is regulated to 5% or below in practice, however, many manufacturers limit the level of free resorcinol in oxidative hair dyes to 1.25%. Resorcinol is limited to 0.5% in shampoos and hair lotions. Resorcinol is usually present in anti-acne preparations at a maximum concentration of 2%. The concentration of resorcinol can be much higher in peels, in some cases around 50%. Jessner’s solution (resorcinol in ethyl alcohol, 14% w/v; lactic acid, 14%; and salicylic acid, 14%) is commonly used in chemical peeling. A specialized medical use of resorcinol is in biological glues (gelatin–resorcinol–formaldehyde glue) for cardiovascular surgery, in particular aortic operations.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P14650 Gene ID: NA Gene Symbol: Tpo Target Organism: Rattus norvegicus (Rat) Sources: http://www.ncbi.nlm.nih.gov/pubmed/27350053 |
253.0 µM [IC50] | ||
Target ID: Prostaglandin E2 synthesis Sources: http://www.ncbi.nlm.nih.gov/pubmed/7630917 |
10.0 µM [IC50] | ||
Target ID: GO:0097251 Sources: http://www.ncbi.nlm.nih.gov/pubmed/8484008 |
180.0 µM [IC50] | ||
Target ID: Leukotriene E4 biosynthetic process Sources: http://www.ncbi.nlm.nih.gov/pubmed/8484008 |
902.0 µM [IC50] | ||
Target ID: Thromboxane B2 biosynthetic process Sources: http://www.ncbi.nlm.nih.gov/pubmed/8484008 |
25.0 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Resinol Approved UseResorcinol topical (for the skin) is used to treat pain and itching caused by minor cuts and scrapes, burns, insect bites, poison ivy, sunburn, or other skin irritations. Resorcinol topical is also used to treat acne, eczema, psoriasis, seborrhea, corns, calluses, warts, and other skin disorders. Launch Date1991 |
|||
Primary | Resinol Approved UseResorcinol topical (for the skin) is used to treat pain and itching caused by minor cuts and scrapes, burns, insect bites, poison ivy, sunburn, or other skin irritations. Resorcinol topical is also used to treat acne, eczema, psoriasis, seborrhea, corns, calluses, warts, and other skin disorders. Launch Date1989 |
Doses
Dose | Population | Adverse events |
---|---|---|
3 % 1 times / day multiple, topical Recommended Dose: 3 %, 1 times / day Route: topical Route: multiple Dose: 3 %, 1 times / day Sources: |
unhealthy, 14-29 |
Disc. AE: Application site discomfort... AEs leading to discontinuation/dose reduction: Application site discomfort (3.13%) Sources: |
30 mg/kg 1 times / day multiple, topical Overdose Dose: 30 mg/kg, 1 times / day Route: topical Route: multiple Dose: 30 mg/kg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Other AEs: Hypothyroidism... Other AEs: Hypothyroidism Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Application site discomfort | 3.13% Disc. AE |
3 % 1 times / day multiple, topical Recommended Dose: 3 %, 1 times / day Route: topical Route: multiple Dose: 3 %, 1 times / day Sources: |
unhealthy, 14-29 |
Hypothyroidism | 30 mg/kg 1 times / day multiple, topical Overdose Dose: 30 mg/kg, 1 times / day Route: topical Route: multiple Dose: 30 mg/kg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Exogenous ochronosis. An update on clinical features, causative agents and treatment options. | 2001 |
|
Chemical modification of carbonaceous stationary phases by the reduction of diazonium salts. | 2001 Aug 15 |
|
Solid-state supramolecular structures of resorcinol-arylboronic acid compounds. | 2001 Aug 9 |
|
Design, synthesis, and biological evaluation of analogues of the antitumor agent, 2-(4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy)propionic acid (XK469). | 2001 May 24 |
|
The toxicity and fate of phenolic pollutants in the contaminated soils associated with the oil-shale industry. | 2002 |
|
A simple method for the in situ detection of eosinophils. | 2002 Feb 1 |
|
The bromination of acetone. application to multicomponent kinetic determinations. | 2002 Jan |
|
[Peroxidase-catalyzed oxidation of 3,3',5,5'-tetramethylbenzidine in the presence of 2,4-dinitrosoresorcinol and polydisulfide derivatives of resorcinol and 2,4-dinitrosoresorcinol]. | 2002 Mar-Apr |
|
Resorcinol derivatives: a novel template for the development of cannabinoid CB(1)/CB(2) and CB(2)-selective agonists. | 2002 May |
|
New efficient procedure for the use of diethoxyphosphoryl as a protecting group in the synthesis of polyazamacrocycles. Preparation of polyazacyclophanes derived from resorcinol. | 2003 Dec 26 |
|
Determination of major phenolic compounds in water by reversed-phase liquid chromatography after pre-column derivatization with benzoyl chloride. | 2003 Feb 21 |
|
Prenylated flavonoids from the roots of Sophora flavescens with tyrosinase inhibitory activity. | 2003 Jun |
|
Downregulation of NF-kappaB activation in human keratinocytes by melanogenic inhibitors. | 2003 May |
|
Single-crystal-to-single-crystal topochemical polymerizations of a terminal diacetylene: two remarkable transformations give the same conjugated polymer. | 2003 Oct 15 |
|
Development of non-electrophoretic assay method for DNA ligases and its application to screening of chemical inhibitors of DNA ligase I. | 2004 Apr 30 |
|
Preparation of tripyrrane analogues from resorcinol and 2-methylresorcinol for applications in the synthesis of new benziporphyrin systems. | 2004 Jan 21 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/mtm/resorcinol-topical.html
Resorcinol topical 2% ointment:
Apply to affected area not more than 3 to 4 times daily.
Route of Administration:
Topical
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QS01AX06
Created by
admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
|
||
|
NCI_THESAURUS |
C28394
Created by
admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
|
||
|
WHO-ATC |
D10AX02
Created by
admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
|
||
|
CFR |
21 CFR 333.310
Created by
admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
|
||
|
WHO-ATC |
S01AX06
Created by
admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
|
||
|
CFR |
21 CFR 333.320
Created by
admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
|
||
|
WHO-VATC |
QD10AX02
Created by
admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
|
||
|
JECFA EVALUATION |
RESORCINOL
Created by
admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
|
||
|
CFR |
21 CFR 346.20
Created by
admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB11085
Created by
admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
|
PRIMARY | |||
|
1602003
Created by
admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
|
PRIMARY | |||
|
YUL4LO94HK
Created by
admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
|
PRIMARY | |||
|
100000078653
Created by
admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
|
PRIMARY | |||
|
1571
Created by
admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
|
PRIMARY | |||
|
5054
Created by
admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
|
PRIMARY | |||
|
590
Created by
admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
|
PRIMARY | |||
|
RESORCINOL
Created by
admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
|
PRIMARY | |||
|
C031389
Created by
admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
|
PRIMARY | |||
|
C77056
Created by
admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
|
PRIMARY | |||
|
CHEMBL24147
Created by
admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
|
PRIMARY | |||
|
35382
Created by
admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
|
PRIMARY | RxNorm | ||
|
27810
Created by
admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
|
PRIMARY | |||
|
m9546
Created by
admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
|
PRIMARY | Merck Index | ||
|
YUL4LO94HK
Created by
admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
|
PRIMARY | |||
|
3524
Created by
admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
|
PRIMARY | |||
|
SUB15120MIG
Created by
admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
|
PRIMARY | |||
|
DTXSID2021238
Created by
admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
|
PRIMARY | |||
|
203-585-2
Created by
admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
|
PRIMARY | |||
|
722
Created by
admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
|
PRIMARY | |||
|
108-46-3
Created by
admin on Mon Mar 31 17:33:39 GMT 2025 , Edited by admin on Mon Mar 31 17:33:39 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)